Cholangiocarcinoma

Beyond Pathology: DNA/RNA Sequencing Achieves Near-Double Sensitivity in Detecting Bile Duct Cancer

By MedXY 04/02/2026

A landmark six-year study involving over 2,000 patients at 28 institutions demonstrates that next-generation sequencing of ERCP-obtained specimens achieves 82% sensitivity for neoplastic bile duct strictures, nearly doubling traditional pathology's 44% sensitivity while maintaining 98% specificity.

Clinical Updates news Oncology

Optimizing Immunotherapy in Cholangiocarcinoma: Low-Dose Chemotherapy as a Catalyst for Immune Microenvironment Remodeling

By MedXY 03/07/2026

This review examines how low-dose gemcitabine and cisplatin (LDGC) synergize with anti-PD-L1 therapy in intrahepatic cholangiocarcinoma by reprogramming immunosuppressive SPP1+ macrophages and enhancing CD8+ T-cell cytotoxicity through STAT1/STAT3 modulation.

Gastroenterology news Oncology

Tinengotinib Offers a Potential Breakthrough for FGFR-Inhibitor Resistant Cholangiocarcinoma

By MedXY 01/14/2026

A Phase 2 trial demonstrates that tinengotinib, a multi-kinase inhibitor, shows significant clinical activity in patients with advanced cholangiocarcinoma who have progressed on prior FGFR inhibitors, particularly those with acquired resistance mutations, paving the way for a Phase 3 registration trial.

Gastroenterology news Oncology

Erdafitinib Yields 55% Response Rate in FGFR-Altered Advanced Cholangiocarcinoma: Insights from a Pooled Phase 2 Analysis

By MedXY 01/11/2026

A pooled analysis of the RAGNAR and LUC2001 trials demonstrates that erdafitinib provides a robust objective response rate of 55% and a median overall survival of 18.1 months in pretreated patients with FGFR-altered advanced cholangiocarcinoma.

Gastroenterology news Oncology

MAPK Pathway Mutations Drive Resistance to Ivosidenib in IDH1-Mutant Cholangiocarcinoma by Blunting Interferon Signaling

By MedXY 01/11/2026

A comprehensive longitudinal ctDNA analysis of patients from the ClarIDHy phase III trial reveals that MAPK pathway alterations, including KRAS and NRAS mutations, are primary drivers of acquired resistance to ivosidenib by suppressing critical interferon-gamma-mediated antitumor responses.